Circulating tumor DNA and late recurrence in high-risk, hormone receptor-positive, HER2-negative breast cancer: An updated analysis of the CHiRP study Read more about Circulating tumor DNA and late recurrence in high-risk, hormone receptor-positive, HER2-negative breast cancer: An updated analysis of the CHiRP study
Circulating tumor DNA (ctDNA) and late recurrence in high-risk, hormone receptor–positive, HER2-negative breast cancer (CHiRP) Read more about Circulating tumor DNA (ctDNA) and late recurrence in high-risk, hormone receptor–positive, HER2-negative breast cancer (CHiRP)
Molecular Residual Disease (MRD) Detection in HPV-Negative Head and Neck Cancer Read more about Molecular Residual Disease (MRD) Detection in HPV-Negative Head and Neck Cancer
Genomic Profiles of Early-Stage Non-Small Cell Lung Cancer Patients, and Association with Pre-Treatment Blood Circulating Tumor DNA Detection and Levels Read more about Genomic Profiles of Early-Stage Non-Small Cell Lung Cancer Patients, and Association with Pre-Treatment Blood Circulating Tumor DNA Detection and Levels
Performance Comparison of RaDaR 1.0 and RaDaR ST Assays for Circulating Tumor DNA Detection Across Solid Tumor Types Read more about Performance Comparison of RaDaR 1.0 and RaDaR ST Assays for Circulating Tumor DNA Detection Across Solid Tumor Types
Detection of circulating tumor DNA following neoadjuvant chemotherapy and surgery to anticipate early relapse in ER positive and HER2 negative breast cancer: Analysis from the PENELOPE-B trial Read more about Detection of circulating tumor DNA following neoadjuvant chemotherapy and surgery to anticipate early relapse in ER positive and HER2 negative breast cancer: Analysis from the PENELOPE-B trial
Sensitive detection of ctDNA in early-stage non-small cell lung cancer patients with a personalized sequencing assay Read more about Sensitive detection of ctDNA in early-stage non-small cell lung cancer patients with a personalized sequencing assay
Role of circulating tumor DNA (ctDNA) from Liquid Biopsy in Early Stage NSCLC Resected Lung Tumor Investigation (LIBERTI) Read more about Role of circulating tumor DNA (ctDNA) from Liquid Biopsy in Early Stage NSCLC Resected Lung Tumor Investigation (LIBERTI)
Analytical development of the RaDaRTM assay, a highly sensitive and specific assay for the monitoring of minimal residual disease Read more about Analytical development of the RaDaRTM assay, a highly sensitive and specific assay for the monitoring of minimal residual disease
Personalized circulating tumor DNA analysis in head and neck squamous cell carcinoma: preliminary results of the Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS) study Read more about Personalized circulating tumor DNA analysis in head and neck squamous cell carcinoma: preliminary results of the Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS) study